Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03175367 · ClinicalTrials.gov registry record · Phase 2
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT03175367 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 272 participants.
The verdict
NCT03175367, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.
Interventions
- DRUG Matching placebo
- DRUG Evinacumab
- OTHER Background Lipid Modifying Therapy (LMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2017-11-10 |
| Est. Completion | 2020-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03175367
The ClinicalTrials.gov registry entry for NCT03175367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching placebo is the first listed.
NCT03175367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03175367 about?
NCT03175367 is a clinical study titled "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia". The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated...
What is the current status of trial NCT03175367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2017-11-10. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT03175367?
The interventions under investigation include: Matching placebo (DRUG), Evinacumab (DRUG), Background Lipid Modifying Therapy (LMT) (OTHER).
Who is sponsoring clinical trial NCT03175367?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.